Sunlenca 300 mg film-coated tablets, BICTEGRAVIR 75 MG/LENACAPAVIR 50 MG FDC TABLETS
GS-US-621-6463
Phase 3 small_molecule active
Quick answer
Sunlenca 300 mg film-coated tablets, BICTEGRAVIR 75 MG/LENACAPAVIR 50 MG FDC TABLETS for HIV-1 Infection is a Phase 3 program (small_molecule) at Gilead Sciences International Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Gilead Sciences International Limited
- Indication
- HIV-1 Infection
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active